Solensia (frunevetmab) 7mg (2 Vials)

PRESCRIPTION REQUIRED FOR THIS ITEM

This item is a prescription medication. A prescription is required from your veterinarian before we can supply this product. Please ensure that you have read the "How to Order" page before ordering this item.

All of Pet Care Pharmacy’s prescription medications are APVMA or TGA approved and are also identical to those supplied by your veterinarian.

Description

• Solensia (frunevetmab) is indicated for the alleviation of pain associated with osteoarthritis in cats.
• Solensia is a felinised therapeutic monoclonal antibody that neutralises Nerve Growth Factor (NGF). The inhibition of NGF-mediated cell signalling has been demonstrated to provide relief from pain associated with osteoarthritis.

Recommendations for use

Solensia alleviates pain associated with osteoarthritis

Key Features 

• A once-a-month subcutaneous injection
• Works differents to NSAIDs by specifically targeting Nerve Growth Factor (NGF) a key player in OA pain
• Solensia is eliminated via normal protein degradation pathways —just like naturally produced antibodies — with minimal impact on the liver, kidneys and GIT
• Well-tolerated even for cats with stage 1 and 2 chronic renal disease
• Solensia is a long-acting and well-tolerated pain medication for cats with OA pain
• No known interactions with other medicinal product such as vaccines, parasiticides, nutritional supplements, antimicrobials

Dosage

• The recommended dosage is 1 – 2.8 mg/kg bodyweight, administered subcutaneously, once a month.
• For cats between 2.5 and 7 kg, administer the entire contents (1 mL) of one vial.
• For cats above 7 kg, the contents of more than one vial are required to constitute a single dose. In those cases, withdraw the entire contents from each required vial into the same syringe.
• Dose according to the dosing chart below:

  Storage

• Store between 2 °C and 8 °C (refrigerate, do not freeze)
• Store in the original package
• Protect from light
• Avoid excessive shaking
• Once opened, contents of the vial should be used immediately and any remaining solution should be disposed

Safety directions
Pregnant women, women trying to conceive, and breast feeding women should take extreme care to avoid accidental self-injection or needle stick injuries. Consult a medical practitioner if such an injection occurs. Wash hands after use.

Additional user safety

• Take care to avoid self-injection. In case of accidental self-injection, seek medical advice immediately and show the package leaflet or label to the Medical Practitioner.
• For pregnant women, women trying to conceive, and breastfeeding women, the importance of Nerve Growth Factor (NGF) in ensuring normal foetal nervous system development is well established and laboratory studies conducted on non-human primates with human anti-NGF antibodies have shown evidence of reproductive and developmental toxicity.
• Pregnant women, women trying to conceive, and breastfeeding women should take extreme care to avoid accidental self-injection or needle stick injuries.
• Consult a Medical Practitioner if such an injection occurs.
• Hypersensitivity reactions, including anaphylaxis, could potentially occur in the case of accidental self-injection. Repeated self-administration may increase the risk of hypersensitivity reactions.
• Wash hands after use.

First Aid Statement
If poisoning occurs, contact a doctor or Poisons Information Centre. Phone Australia 131126.

ANIMAL SAFETY

Contraindications

• This product must not be used in cats intended for breeding.
• This product must not be used in pregnant or lactating cats as Nerve Growth Factor (NGF) plays a key role in foetal nervous system development.
• This product must not be used in cats under 12 months of age, weighing less than 2.5 kg.
• This product must not be used in cats with hypersensitivity to frunevetmab.

Side Effects

• Focal skin reactions (e.g. pruritis, dermatitis and alopecia) occurred commonly in studies (i.e. between 1 and 10 animals in every 100 animals treated).

Precautions

• There are no safety data on the current use of non-steroidal anti-inflammatory drugs (NSAIDs) and frunevetmab in the cat.
• The safety and efficacy of this product has not been investigated in cats with kidney disease IRIS stages 3 and 4. Use of the product in such cases should be based on a benefit-risk
• Assessment performed by the responsible veterinarian.
• This veterinary medicinal product may induce transient or persistent anti-drug antibodies. The induction of such antibodies may reduce the efficacy of the product although this was not observed during the 84 days of the pivotal clinical trial. No information is available for longer duration treatment.